Gastroenterology Section, Medicine Department, Hospital Clínico Universidad de Chile, Santiago, Chile.
Critical Patient Care Unit, Medicine Department, Hospital Clínico Universidad de Chile, Santiago, Chile.
Ann Hepatol. 2024 Jul-Aug;29(4):101511. doi: 10.1016/j.aohep.2024.101511. Epub 2024 May 6.
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis.
This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021-Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan®) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann-Whitney U test, and logistic regression models were used (p < 0.05).
The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (p = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06-3.04; p = 0.029).
MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies.
患有代谢功能障碍相关脂肪性肝病 (MASLD) 的患者心血管风险增加。相反,非酒精性脂肪性肝病 (NAFLD) 在冠心病 (CHD) 患者中非常普遍。然而,尚不清楚是否患有严重 CHD 的患者肝纤维化的频率更高。本研究旨在确定 CHD 患者中 MASLD 和肝纤维化的频率,并评估冠状动脉狭窄是否与 MASLD 和纤维化有显著关联。
这项观察性和分析性研究纳入了 2021 年 7 月至 2022 年 7 月因疑似冠心病而行冠状动脉造影的无任何已知肝病的成年患者。确定是否存在严重 CHD(至少一条冠状动脉狭窄 > 50%)。在冠状动脉造影研究后 6 个月内进行肝脏弹性成像(FibroScan®)以确定肝纤维化,即肝脏硬度测量值(> 6.5 Kpa)。使用 Fisher 检验、Mann-Whitney U 检验和逻辑回归模型(p < 0.05)。
该研究纳入了 113 名患者(76%为男性,平均年龄:63 岁[标准差:9.9]),其中 72%存在严重 CHD。MASLD 的患病率为 52%。12%的患者存在肝纤维化,且所有严重 CHD 组患者均存在肝纤维化(p = 0.007)。CHD 中存在的狭窄血管数量增加,肝纤维化的概率增加(比值比,1.79;95%置信区间,1.06-3.04;p = 0.029)。
患有严重 CHD 但无已知肝损伤的患者中 MASLD 患病率很高。这些数据表明,CHD 患者应进行 MASLD 和肝纤维化的检查。在进一步的研究中应评估混杂变量的存在,特别是 2 型糖尿病的存在。